Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31582781 | 0.87 | F2R (0.44) | F2RMAPTKMT2AMEN1KDM4E | |
| SCHEMBL25204030 | 0.83 | CES2 (0.53) | MAPTKMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL25208513 | 0.80 | CES2 (0.53) | MAPTKMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL612915 | 0.80 | SLC6A4 (0.47) | F2RMAPTKMT2AMEN1KDM4E | |
| SCHEMBL27583391 | 0.80 | F2R (0.48) | F2RMAPTKMT2AMEN1KDM4E | |
| SCHEMBL1772283 | 0.79 | MAPT (0.51) | MAPTKMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL18797551 | 0.78 | PTPN1 (0.52) | F2RMAPTTP53PKMCES2 | |
| SCHEMBL29280610 | 0.77 | CES2 (0.44) | F2RNPC1RAB9APKMKDR | |
| SCHEMBL6744202 | 0.77 | F2R (0.56) | F2RMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27223588 | 0.76 | KDM4E (0.54) | MAPTKMT2AKDM4ESMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102439010-A | Process for the production of fused, tricyclic sulfonamides | ELAN PHARM INC | 2012-05-02 | — | — | CN | disclosed |
| EP-2411388-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| WO-2010111418-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111418-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | CBR3, DRD4, SBDS | F2R 3728/4885MAPT 4298/4885KMT2A 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.